To describe the demographics, clinical characteristics, treatment patterns and clinical outcomes of chronic inflammatory demyelinating polyneuropathy (CIDP), Guillain-Barre Syndrome (GBS), and heredofamilial amyloidosis (hATTR) adult patients at a single U.K. centre.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Patient baseline characteristics
Timeframe: At diagnosis
Grip strength test
Timeframe: At diagnosis or pre-Ig treatment initiation.
9-hole peg test
Timeframe: At diagnosis or pre-Ig treatment initiation.
10 meter walk test
Timeframe: At diagnosis or pre-Ig treatment initiation.
Overall neuropathy limitations scale
Timeframe: At diagnosis or pre-Ig treatment initiation.
Berg balance test
Timeframe: At diagnosis or pre-Ig treatment initiation.
Medical research council muscle strength score
Timeframe: At diagnosis or pre-Ig treatment initiation.
Inflammatory neuropathy cause and treatment (INCAT) sensory sum (ISS) score
Timeframe: At diagnosis or pre-Ig treatment initiation up to December 31, 2022 or death or lost-to-follow-up, whichever comes first.